Acute Ischemic Stroke Diagnosis Global Market Report 2024

The acute ischemic stroke diagnosis market size has grown strongly in recent years. It will grow from $2.14 billion in 2023 to $2.31 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth observed in the historical period can be attributed to several factors, including the rise in cardiovascular risk factors, increased adoption of telemedicine, the establishment of specialized stroke centers, a growing aging population, and advancements in thrombolytic therapies. These elements collectively contributed to the overall progress and improvement in the field of acute ischemic stroke diagnosis and treatment.

The acute ischemic stroke diagnosis market size is expected to see strong growth in the next few years. It will grow to $2.99 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The anticipated growth in the forecast period can be attributed to various factors, including the integration of remote monitoring technologies, the adoption of patient-centric healthcare models, the incorporation of wearable devices, the development of point-of-care testing devices, and the expansion of mobile stroke units. Key trends expected in the forecast period include advancements in imaging technologies, the application of artificial intelligence in diagnostics and treatment, innovations in genetic and biomarker products, the use of blockchain for data security, and the integration of augmented reality in healthcare applications. These trends collectively contribute to the continued evolution and improvement of acute ischemic stroke diagnosis and care.

The anticipated surge in acute ischemic stroke cases stands as a driving force behind the projected growth of the acute ischemic stroke diagnosis market. This medical condition, stemming from inadequate blood supply to the brain, leads to severe brain cell damage and qualifies as a critical medical emergency. Prompt diagnosis of acute ischemic stroke becomes instrumental in its treatment, mitigating potential brain damage, and curtailing subsequent repercussions. An illustrative instance from March 2023 reported by the Centers for Disease Control and Prevention highlighted an increase in stroke-related fatalities from 38.8 per 100,000 in 2020 to 41.1 per 100,000 in 2021. In the United States alone, the annual occurrence exceeds 795,000 strokes, with approximately 610,000 being first-time strokes, and approximately 87% of these strokes are ischemic in nature, indicating impaired blood flow to the brain. Hence, the escalating prevalence of acute ischemic stroke cases drives the expansion of the acute ischemic stroke diagnosis market.

The burgeoning elderly demographic is poised to significantly contribute to the growth of the acute ischemic stroke diagnosis market in the foreseeable future. Defined as individuals aged 65 and above, this demographic segment presents distinct health and social requisites coupled with vulnerabilities associated with the aging process, such as the prevalence of multiple chronic ailments and physical limitations. The elderly demographic assumes a pivotal role in acute ischemic stroke diagnosis, primarily due to their heightened susceptibility compared to younger age groups. Key facets crucial in acute ischemic stroke diagnosis encompass early identification, treatment modalities, and concurrent health conditions. For instance, insights from the World Health Organization in October 2022 indicated that by 2030, 1 in every 6 individuals globally will surpass 60 years of age, reaching a tally of 1.4 billion, up from 1 billion in 2020. Moreover, the worldwide population aged 60 and above is projected to double to 2.1 billion by 2050, with an additional 426 million individuals expected to cross the 80-year milestone during this period. Hence, the burgeoning elderly populace is a significant catalyst propelling the expansion of the acute ischemic stroke diagnosis market.

The acute ischemic stroke diagnosis market is witnessing a prominent trend favoring product innovations, capturing widespread attention. Leading companies within this domain are dedicatedly engaged in pioneering novel products to uphold their market standing. An exemplary instance occurred in February 2022 when Imperative Care Inc., a US-based manufacturer of medical equipment, unveiled the Zoom POD Aspiration Tubing - an innovative advancement aimed at enhancing stroke therapy. Distinguished as the first sterile field clot filter device, the Zoom POD facilitates expedited mechanical thrombectomy procedures for individuals afflicted with ischemic stroke. This groundbreaking device integrates seamlessly into the aspiration tube, significantly reducing the distance between aspiration and filtration while maintaining optimal aspiration strength. The Zoom POD expedites a critical phase of treatment by providing swift visualization to physicians, confirming efficient clot removal, thereby streamlining the therapeutic process.

Major players in the acute ischemic stroke diagnosis market are strategically forging partnerships to gain a competitive edge. These collaborations are strategically aimed at bolstering the development and accessibility of cutting-edge diagnostic tools crucial for accurate and timely stroke diagnosis. Notably, in October 2023, Brainomix Ltd., a US-based medtech company powered by AI solutions, joined forces with Nanoflex Robotics AG, a Switzerland-based developer specializing in soft robotic systems. Their partnership targets the creation of an AI robotics platform dedicated to acute ischemic stroke treatment. This innovative platform involves AI-assisted magnetic navigation systems tailored for stroke-related robotic surgical tools. The amalgamation of their technologies aims to introduce an AI-driven navigation tool facilitating catheters and other devices in navigating the vascular system. This collaborative project aspires to leverage artificial intelligence to enhance Nanoflex Robotics' advanced magnetic robotic navigation system, potentially pioneering remote thrombectomy - a groundbreaking shift in stroke therapy possibilities. This groundbreaking endeavor is anticipated to significantly impact stroke therapy, potentially enhancing patient outcomes by revolutionizing the treatment landscape.

In November 2021, Royal Philips, a Netherlands-based hospital and healthcare company, completed the acquisition of Cardiologs for an undisclosed amount. This strategic move allowed Philips to enhance its cardiac monitoring and diagnostics portfolio by incorporating innovative software technologies, electrocardiogram (ECG) analysis, and reporting services. Cardiologs, based in France, is a medical technology company specializing in ECG, a diagnostic tool relevant to acute ischemic stroke and other cardiovascular conditions.

Major companies operating in the acute ischemic stroke diagnosis market report are Cardinal Health Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Sanofi-Aventis LLC, Abbott Laboratories, Medtronic plc, Siemens Healthineers AG, Philips Healthcare, Stryker Corporation, GE HealthCare Technologies Inc., Boston Scientific Corporation, Genentech Inc., Nihon Kohden Corporation, Neusoft Medical Systems Co. Ltd., Penumbra Inc., Insera Therapeutics LLC, MicroVention Inc., FUJIFILM Medical Systems, Canon Medical Systems Corporation, Silk Road Medical Inc., Samsung Neurologica Corporation, Mentice AB, NICO Corporation, Imperative Care Inc., Olea Medical, NovaSignal Corporation, iSchemaView Inc., Hyperfine Research Inc., Perfuze Ltd.

North America was the largest region in the acute ischemic stroke diagnosis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute ischemic stroke diagnosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute ischemic stroke diagnosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of acute ischemic stroke diagnosis include computed tomography (CT), magnetic resonance imaging (MRI), carotid ultrasound, cerebral angiography, electrocardiography (ECG), echocardiography, and other relevant methods. Computed tomography (CT) involves the creation of detailed images of various body parts using computer technology connected to an X-ray machine. Various types of surgeries are associated with acute ischemic stroke treatment, including carotid endarterectomy, angioplasty, and endovascular mechanical thrombectomy. These surgical procedures find application in various treatment approaches, such as the use of tissue plasminogen activator (TPA), anticoagulants, antiplatelet medications, and antihypertensive drugs.

The acute ischemic stroke diagnosis market research report is one of a series of new reports that provides acute ischemic stroke diagnosis market statistics, including acute ischemic stroke diagnosis industry global market size, regional shares, competitors with an acute ischemic stroke diagnosis market share, detailed acute ischemic stroke diagnosis market segments, market trends and opportunities, and any further data you may need to thrive in the acute ischemic stroke diagnosis industry. This acute ischemic stroke diagnosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute ischemic stroke (AIS) diagnosis market includes revenues earned by entities through physical exams, thrombolysis, blood tests, and other imaging techniques. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.